BFA
CYTK icon

BlackRock Fund Advisors’s Cytokinetics CYTK Stock Holding History

BlackRock Fund Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$19.9M Buy
1,633,726
+699,699
+75% +$7.43M ﹤0.01% 2188
2016
Q3 		$8.57M Buy
934,027
+52,043
+6% +$543K ﹤0.01% 2556
2016
Q2 		$8.37M Sell
881,984
-5,973
-0.7% -$49K ﹤0.01% 2505
2016
Q1 		$6.26M Sell
887,957
-31,531
-3% -$230K ﹤0.01% 2625
2015
Q4 		$9.62M Buy
919,488
+31,188
+4% +$306K ﹤0.01% 2469
2015
Q3 		$5.94M Sell
888,300
-10,610
-1% -$72.4K ﹤0.01% 2697
2015
Q2 		$6.04M Sell
898,910
-46,618
-5% -$306K ﹤0.01% 2816
2015
Q1 		$6.41M Buy
945,528
+1,355
+0.1% +$10.1K ﹤0.01% 2703
2014
Q4 		$7.56M Buy
944,173
+127,931
+16% +$549K ﹤0.01% 2627
2014
Q3 		$2.87M Sell
816,242
-26,955
-3% -$113K ﹤0.01% 3041
2014
Q2 		$4.03M Sell
843,197
-36,492
-4% -$223K ﹤0.01% 2952
2014
Q1 		$8.36M Buy
879,689
+153,801
+21% +$1.39M ﹤0.01% 2503
2013
Q4 		$4.72M Sell
725,888
-21,433
-3% -$141K ﹤0.01% 2858
2013
Q3 		$5.66M Buy
+747,321
New +$8.02M ﹤0.01% 2720

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Fund Advisors's CYTK Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Cytokinetics (CYTK) stake by 75% in Q4 2016, buying an estimated $7.43M and bringing the position to 1,633,726 shares worth $19.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2188.

BlackRock Fund Advisors first reported a position in CYTK in Q3 2013 and has held it in 14 quarters since. 101 funds tracked by Wall St. Rank hold CYTK as of Q4 2016.

  • BlackRock Fund Advisors held 1,633,726 shares of Cytokinetics worth $19.9M as of Q4 2016.
  • BlackRock Fund Advisors bought 699,699 Cytokinetics shares in Q4 2016, an estimated $7.43M.
  • Cytokinetics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2188 holding.
  • BlackRock Fund Advisors first reported a position in Cytokinetics in Q3 2013 and has held it in 14 quarters since.
  • 101 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.